Julia Ding

Julia Ding is leading a critical function within biologic development at Bristol Myers Squibb. She is leading a diverse and cross-functional team responsible for: 

• Leading BMS global biologics PAT strategy and implementation
• Advancing new technologies in the area of PAT, Rapid analysis, Automation and High-throughput analytical development
• Enabling and advancing analytical methodologies in supporting bioprocess development
• Identifying, managing and integrating risks among process development, analytical development and manufacturing.
• Establishing risk balanced CMC analytical and process development plans.
• Establishing and advancing phase appropriate Biologics CMC analytical strategies across all clinical phases
• Developing and establishing Biologics specifications for clinical phase biologics

Julia Ding has over 20 years experience in biologics analytical and CMC development. Prior to joining BMS, she has held roles of increasing analytical leadership responsibilities both at Waters Corporation and PPD. Julia obtained her Ph.D. in Physical Organic chemistry from Emory University and postdoc from the University of California at Berkeley.